Soluble TIM-3 level was highly increased in the blood plasma of AML patients and was shown to prevent secretion of interleukin-2 (IL-2) required for the activation of NK cells and cytotoxic lymphoid cells (41). The gene discussed is IL2; the disease is acute myeloid leukemia.